Drugs / MK0773
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01017458 | Jun 2007 → Aug 2008 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01011725 | Nov 2005 → Apr 2006 | osteoporosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00529659 | Oct 2007 → Oct 2009 | muscular atrophy | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK0773 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01017458 ↗ |
| Known as | PF-05314882 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3221237 ↗ |
| Modality | Other / unclassified | “MK-0773 is a selective androgen receptor modulator designed to improve muscle function while minimizing effects on other tissues.” PMID 23732550 ↗ 2013 |
| Route | Oral | “25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks” NCT01011725 ↗ |
| Target | AR | “Androgen Receptor modulator” CHEMBL3221237 ↗ |